You are here
The FDA Approves Dynacin (minocycline HCl) Tablets
DYNACIN® Tablets is a prescription product and will be available in 50 mg., 75 mg. and 100 mg. dosages. DYNACIN® Tablets formulation is the most recent innovation to the DYNACIN® family of products. DYNACIN® Tablets is the only prescription minocycline tablet approved in the United States for the adjunctive treatment of severe acne.
In addition to being the only minocycline tablet on the market, new DYNACIN® Tablets are small, easy-to-swallow, coated tablets suitable for patients who experience difficulty swallowing larger-sized capsules. Additionally, DYNACIN® Tablets incorporates the same dye-free formulation as the capsules to avoid potential allergic reactions in patients with sensitivities to dye additives.
"We are pleased to announce approval of DYNACIN® Tablets, the only prescription minocycline tablet indicated for the adjunctive treatment of severe acne," said Jonah Shacknai, chairman and chief executive officer of Medicis. "Approval of this new dosage form of DYNACIN® has the potential to enhance the brand's already significant success. The new, smaller-sized, coated DYNACIN® Tablets are expected to offer a high degree of patient compliance by providing an easier to swallow form of the most widely prescribed brand of minocycline in dermatology."